Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Data regarding the safety and efficacy of ivabradine use in severely decompensated HFrEF requiring inotropic support is limited to case series.1 This study aimed to evaluate ivabradine safety and tolerability in admitted cardiogenic shock patients who started on dobutamine infusion for inotropic support.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Young Investigator Group of Cardiovascular Research
• Treatments: Dobutamine

Criteria

Inclusion Criteria:

• Decompensated heart failure with reduced ejection fraction (HFrEF) admitted for cardiogenic shock requiring inotropic support.

Exclusion Criteria:

• Decompensated heart failure with reduced ejection fraction (HFrEF) not requiring inotropic support.

• Patients with no oral intake

• Patients who refused to sign the consent